Ginkgo Results Presentation Deck
We believe...
1
Cell programming is
starting to become
mainstream.
We have increased our 2021
outlook for number of new
programs from 23 to 30 due to
higher-than-expected inbound
interest from potential customers
and enhanced credibility from
completing programs.
2
Downstream value will
become more valuable than
Foundry service revenue.
Foundry service revenue de-risks
platform investments, but "wins"
come from successful programs.
We've heard a lot of questions about
how downstream value works so
we're giving 3 near-term case
studies.
3
Delta sucks. And so will the
next thing.
Biosecurity will be a new market
separate from diagnostics and we
are becoming a leader due to our
initial K-12 testing offering. We are
now expecting our revenue to be at
least $75 million for the full year.
H1 UPDATE | AUGUST 2021
GINKGO BIOWORKS
4View entire presentation